Vismodegib (GDC-0449) , ≥98% , 879085-55-9
CAS NO.：879085-55-9
Empirical Formula: C19H14Cl2N2O3S
Molecular Weight: 421.3
MDL number: MFCD12407408
EINECS: 806-752-3
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB479.20 | In Stock |
|
| 50MG | RMB1159.20 | In Stock |
|
| 250MG | RMB1711.20 | In Stock |
|
| 100mg | RMB2356.00 | In Stock |
|
| 1g | RMB4279.20 | In Stock |
|
| 500mg | RMB5839.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 179-181°C |
| Boiling point: | 561.6±50.0 °C(Predicted) |
| Density | 1.440 |
| storage temp. | -20° |
| solubility | Soluble in DMSO (up to 200 mg/ml) or in Ethanol (up to 10 mg/ml with warming) |
| form | White solid. |
| pka | 10.72±0.70(Predicted) |
| color | Off-white or beige |
| Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. |
| InChI | InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24) |
| InChIKey | BPQMGSKTAYIVFO-UHFFFAOYSA-N |
| SMILES | C(NC1=CC=C(Cl)C(C2=NC=CC=C2)=C1)(=O)C1=CC=C(S(C)(=O)=O)C=C1Cl |
Description and Uses
In January 2012, the US FDA approved vismodegib (also referred to as GDC-0449) for the treatment of adults with metastatic basal cell carcinoma (BCC), with locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation. Vismodegib inhibits the Hh sig?naling pathway by functioning as an antagonist of SMO thereby inhibiting the activation of Hedgehog target genes, resulting in decreased downstream pro?duction of proliferation factors. The IC50 of vismodegib in a Hedgehog?responsive cell line derived from human embryonic palatal mesenchyme cells was 2.8 nM. In preclinical in vivostudies, vismodegib at 12.5 mg/kg (bid) caused complete regression of tumors in a Hh pathway dependent medulloblas?tomaallograft model generated from Ptch+/-mice. A synthesis of vismodegib starting from 2-chloro-5-nitro aniline and employing a Negishi coupling with 2-pyridyl zinc iodide as a key step has been reported.
Vismodegib targets the Hedgehog (Hh) pathway. Inhibition of the Hh signaling may be effective in the treatment and prevention of many types of human cancers. Potent Hedgehog inhibitor.
Safety
| Symbol(GHS) |   GHS08,GHS09 |
| Signal word | Danger |
| Hazard statements | H410-H360-H373-H400 |
| Precautionary statements | P260-P314-P501-P273-P391-P501-P273-P391-P501 |
| HS Code | 29333990 |
| Hazardous Substances Data | 879085-55-9(Hazardous Substances Data) |
